Liraglutide
Also known as: Saxenda, Victoza
Liraglutide is a GLP-1 receptor agonist with daily exposure rather than weekly depot kinetics. It supports glucose-dependent insulin secretion and appetite reduction, so ProtoComp treats it as a cabinet signal for lower hunger, nausea watchpoints, and conservative nutrition precision.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
The New England journal of medicine · 2015 · PMID 26132939
FDA-approved daily GLP-1 RA. Saxenda (obesity): titrate to 3 mg daily. Victoza (T2D): 0.6-1.8 mg daily.
No cycle range recorded.
Weekly dose titration (0.6 mg then 1.2 then 1.8 then 2.4 then 3 mg) to minimize GI side effects.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- • History of pancreatitis
Common side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Hypoglycemia (if combined with insulin/sulfonylureas)
- • Headache
Serious risks
- • Acute pancreatitis
- • Gallbladder disease
- • Thyroid C-cell tumors (boxed warning)
- • Renal impairment
Drug interactions
- • Insulin/sulfonylureas (hypoglycemia risk)
- • Delays gastric emptying
Requires monitoring
- • HbA1c
- • Weight
- • Kidney function
Pregnancy / breastfeeding
Not recommended during pregnancy or breastfeeding
- Daily injection is often inferior adherence vs weekly agents
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.